Onconex Thyroid Cancer (Somatic) near me in Bhopal

Every year, about 12,000 men and 33,000 women get thyroid cancer, and about 950 men and 1,100 women die from the disease.

According to Surveillance, Epidemiology, and End Results (SEER) data, 89.9% of patients diagnosed with thyroid cancers have papillary thyroid carcinoma (PTC), 4.5% follicular thyroid carcinoma (FTC), 1.5% Hurthle-cell carcinoma, and 0.8% anaplastic thyroid carcinoma (ATC).

NGS offers diagnostic improvements for fine needle aspiration (FNA) cytology of thyroid with indeterminate features. It also contributes to patient management, providing risk stratification of patients based on the risk of malignancy. Mutations in Telomerase Reverse Transcriptase (TERT) are very common in thyroid cancers, from 22% to 23% in papillary thyroid carcinoma (PTC) to over 50% in poorly differentiated thyroid carcinomas (PDTC) and anaplastic thyroid carcinoma (ATCs). The BRAF V600E mutation is the most common genetic mutation detected in patients with PTC and occurs in approximately 45% of patients.

NGS enables massively parallel sequencing for a large number of genes with accurate reads while being relatively inexpensive.

Clinical Utility:

• Identify Driver Mutations - mutation in the DNA Sequence that cause cells to become cancers, grow & spread in body.
• Drug profiling for Chemotherapy & Targeted Drugs.
• Predictive genomic biomarker identification to guide the therapeutic process.
• The targeted NGS panel offers wide coverage and in-depth analysis to detect the known and novel variants.
• The multigene approach reduces the time for diagnosis providing a more economical solution.

Panel Covered:

• Comprehensive genomic profiling for 70 cancer genes associated with thyroid cancers.
• Screening for clinically significant genes based on National Comprehensive Cancer Network (NCCN) guidelines.
• Genetic counselling to guide through the report and discuss the available management & treatment options in case of clinical findings.
• Reporting - Pathogenic and Likely Pathogenic Variants are reported following the ACMG recommended guidelines.
• Best in class Bioinformatics pipeline for the most accurate analysis by our experienced Bioinformatics team.

Who Should Get Tested?

• Patients diagnosed with thyroid cancer seeking personalized treatment options.
• Individuals with a family history of thyroid cancers.
• Patients with mutations in genes like TERT or BRAF V600E.
• Clinicians looking for comprehensive genomic profiling to inform targeted therapies.

What Does the Report Tell Me?

The  Onconex Thyroid Cancer (Somatic) test report provides detailed insights into the genetic mutations driving thyroid cancers. It identifies driver mutations, informs drug profiling for chemotherapy and targeted drugs, and highlights predictive genomic biomarkers to guide the therapeutic process. The report includes pathogenic and likely pathogenic variants following ACMG guidelines, offering a clear understanding of the molecular underpinnings of the tumor and potential treatment options.

Next Steps Post Getting the Report:

After receiving the Onconex Thyroid Cancer (Somatic) test report, the following steps are recommended:

• Schedule a genetic counseling session to interpret the results and discuss available management and treatment options.
• Discuss the report with your healthcare provider to tailor the treatment plan based on the genetic profile of the tumor.
• Consider targeted therapies and other personalized treatment options informed by the genomic insights provided in the report.
• Utilize the free genetic counseling offered to navigate the results, explore therapeutic strategies, and make informed decisions about your treatment plan.

Note: Pre-test & post-test genetic counseling can be provided. If interested please send the request to this email id: [email protected]

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.